TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05884970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
Study: NCT06586320

Intervention type: DRUG
Group type: OTHER
Intervention: 150% of their routine home dopaminergic medications dose right in the clinic
Description: IPD subjects will be informed head of time not to take their dopaminergic medications and other Parkinson's non-dopaminergic medications such as anticholinergics, NMDA inhibitors, and adenosine blockers for at least 12 hours prior to their initial procedure. Immediately, after conducting both hand movement and eye movement tests, the patient will take 150% of their routine home dopaminergic medications dose right in the clinic. They will also take their non-dopaminergic medications doses similar to home dose with no change. This will be under the supervision of their treating movement disorders specialist and study PI.

Intervention type: DEVICE
Group type: OTHER
Intervention: Evaluation of mathematical models
Description: Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras
Study: NCT06565039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supira System
Description: The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
Study: NCT05384483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine 1.5 to 3 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04700800

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake
Study: NCT05231122

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04700800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of Amino Acids
Description: Intravenous infusion of mixture of amino acids
Study: NCT05222945

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies and bloood samplings
Description: blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
Study: NCT05886244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
Study: NCT06582732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intracameral Implant exchanged at Month 12
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intracameral Implant exchanged at Month 3
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intracameral Implant exchanged at Month 6
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
Study: NCT05231122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06582732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intracameral Implant exchanged at Month 24
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
Study: NCT06175975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
Description: The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
Study: NCT05310656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Empowerment Programme
Description: Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
Study: NCT06582732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost intracameral implant exchanged at Month 21
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost intracameral implant exchanged at Month 18
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
Study: NCT06079658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss
Description: This intervention seeks to investigate two different caloric restriction protocol on fat mass.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss
Description: This intervention seeks to investigate two different caloric restriction protocol on fat mass.
Study: NCT05906979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAHOLA (digital health assistant)
Description: Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAHOLA (digital health assistant)
Description: Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
Study: NCT06582732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost intracameral implant exchanged at Month 15
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
Study: NCT05906979

Intervention type: OTHER
Group type: OTHER
Intervention: Standard information on alcohol use and health
Description: A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
Study: NCT05947903

Intervention type: OTHER
Intervention: Administration of the EUonQoL-Kit - Active Treatment questionnaire
Description: Electronic questionnaire to be administered to patients in active treatment.

Intervention type: OTHER
Intervention: Administration of the EUonQoL-Kit - Survivors questionnaire
Description: Electronic questionnaire to be administered to cancer survivors.
Study: NCT05231122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05947903

Intervention type: OTHER
Intervention: Administration of the EUonQoL-Kit - Palliative Care questionnaire
Description: Electronic questionnaire to be administered to patients in palliative care.
Study: NCT05231122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06310993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise programme is the intervention for this study
Study: NCT06641778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Patients in the experimental group received conventional antibiotic therapy plus fecal microbiota transplantation, and the efficacy was compared with that in the control group
Study: NCT05497206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System
Description: Total Hip Arthroplasty
Study: NCT06405412

Intervention type: OTHER
Intervention: MUST malnutrition score
Description: MUST malnutrition score

Intervention type: OTHER
Intervention: MUST malnutrition score
Description: MUST malnutrition score

Intervention type: OTHER
Intervention: MUST malnutrition score
Description: MUST malnutrition score
Study: NCT06434636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transamine 10% IV/IM Solution for Injection
Description: 10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within 15 minutes.
Study: NCT05829681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Participants will receive a 5-day course of 10x daily rTMS, with sessions delivered hourly. Each session will deliver up to 1800 pulses of theta-burst stimulation per target.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Participants will receive a 5-day course of 10x daily rTMS, with sessions delivered hourly. Each session will deliver up to 1800 pulses of theta-burst stimulation per target.
Study: NCT03995043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Support
Description: Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Support
Description: Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to contraception
Description: Will be provided by the mobile reproductive health team at contraceptive access points, and, at the health facility partners who will be providing full reproductive health services to program participants and will be the access points for Intra-Uterine Device (IUD) insertion where requested and medically suitable. Results of point of care urine HCG (pregnancy) testing (voluntary at enrollment and mandatory when accessing contraceptive services)
Study: NCT05884970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
Study: NCT05091086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Active comparator: persistent treatment of denosumab. Experimental: alternating treatment with zoledronate and denosumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Active comparator: persistent treatment of denosumab. Experimental: alternating treatment with zoledronate and denosumab
Study: NCT05735158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB105
Description: Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually matched excipient gel
Study: NCT05049681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
Study: NCT04810455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purrble
Description: The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control toy
Description: The selected active control toy is the Wild Republic 8'' Hedgehog animal. The selection process was guided by: the plush toy needed to have analogous size, weight, quality of materials, and at least similar (if not higher) visual appeal. The investigators also made sure to include the design characteristics our prior work suggested were important for the narrative around the toy. These were selecting a similarly stylised animal (to enable emotion projection and feelings of care), as well as no visible mouth on the toy (to prevent setting an expectation about the toy's emotional state as a mouth would imply an emotional expression). Additionally, the investigators have adapted the one-page parent-facing descriptions of the narrative that come with Purrble also for the active control unit: as such, the active control families will receive the same general narrative-without the explicit mentions of the toy interactivity-and the same suggested activities for parents.
Study: NCT05141786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study: NCT05227677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GA guided anti-diabetic therapy adjustment
Description: The GA concentration will be measured at 4-week intervals in both groups. The anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: current guidelines to adjust treatment
Description: The GA concentration will be measured at 4-week intervals. Investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
Study: NCT05584020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Repair
Description: Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
Study: NCT05049681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg, q.d.po
Study: NCT05584020

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ACL Reconstruction
Description: Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
Study: NCT06037616

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: powerpoint and tutor
Description: Powerpoint on indication of skin suture and tutor for the skill to perform skin suture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: powerpoint and tutor
Description: Powerpoint on indication of skin suture and tutor for the skill to perform skin suture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: powerpoint and tutor
Description: Powerpoint on indication of skin suture and tutor for the skill to perform skin suture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: powerpoint and tutor
Description: Powerpoint on indication of skin suture and tutor for the skill to perform skin suture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video skill
Description: Video showing skill to perform a skin suture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video skill
Description: Video showing skill to perform a skin suture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video errors
Description: Video showing errors of skin suture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video errors
Description: Video showing errors of skin suture
Study: NCT06434636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: %0.9 Saline
Description: 100 cc %0.9 Normal Saline will be injected through the appropriate vascular access within 15 minutes
Study: NCT05158699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Description: Bromfenac topical eye drops (Yellox)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone topical eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally